Abstract
Background
There is controversy regarding the potential effects of statin therapy on mortality in patients with heart failure. The present study analyzed the possible effects of statin therapy on morbidity and mortality in patients with diastolic heart failure over long‐term follow‐up.
Hypothesis
To evaluate potential effect of statin therapy on hospitalization rate and mortality in patients with diastolic heart failure.
Methods
Patients with preserved left ventricular ejection fraction (≥50%), hospitalized for clinical symptoms of heart failure were evaluated. Patients on statin therapy started at or prior to their first heart failure admission represented group 1 and patients without statin therapy represented group 2. The effects of statins on hospitalization rates and mortality were assessed during a 5 year follow‐up.
Results
A total of 270 patients (group 1 n = 81; group 2 n = 189) were followed over 5 years. Patients on statins demonstrated improved survival compared to patients without statin therapy (hazard ratio [HR] = 0.65, 95% confidence interval [CI]: 0.45–0.95, P = .029). The survival benefit was maintained after adjusting for differences in baseline characteristics, comorbidities, and other medications. There was no significant difference in the mean cardiovascular hospitalization rate (3.0 ± 3.2 vs 3.8 ± 4.7, P = .23) and in overall hospitalization rate (7.1 ± 6.3 vs 7.8 ± 7.7, P = .52) between groups 1 and 2, respectively.
Conclusion
Statin therapy appears to be associated with improved survival in patients with diastolic heart failure. Copyright © 2009 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (301.5 KB).
References
- 1. Yamada T, Node K, Mine T, et al. Long‐term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J 2007; 153: 1055e1–8. [DOI] [PubMed] [Google Scholar]
- 2. Khush KK, Waters DD, Bittner V, et al. Effect of high‐dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007; 115: 576–583. [DOI] [PubMed] [Google Scholar]
- 3. Domanski M, Coady S, Fleg J, Tian X, Sachdev V. Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the β‐Blocker Evaluation of Survival Trail [BEST]). Am J Cardiol 2007; 99: 1448–1450. [DOI] [PubMed] [Google Scholar]
- 4. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248–2261. [DOI] [PubMed] [Google Scholar]
- 5. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005; 112: 357–363. [DOI] [PubMed] [Google Scholar]
- 6. Shah R, Wang Y, Foody JM. Effects of statins, angiotensin‐converting enzyme inhibitors, and β‐blockers on survival in patients ≥ 65 years of age with heart failure and preserved left ventricular systolic function. Am J Cardiol 2008; 2: 217–222. [DOI] [PubMed] [Google Scholar]
- 7.GISSI‐HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI‐HF trial): a randomised, double blind, placebo‐controlled trial. Lancet 2008; Aug 29. [Epub ahead of print]. [DOI] [PubMed] [Google Scholar]
- 8. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389. [PubMed] [Google Scholar]
- 9. Collins R, Armitage J, Parish S, Sleight P, Peto R; on behalf of the MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high‐risk individuals: a randomised placebo‐controlled trial. Lancet 2002; 360: 7–22.12114036 [Google Scholar]
- 10. Cannon CP, Braunwald E, McCade CH, et al. Intensive versus moderate lipid‐lowering with statins after acute coronary syndrome. N Engl J Med 2004; 350: 1495–1504. [DOI] [PubMed] [Google Scholar]
- 11. Strippoli GFM, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta‐analysis and meta‐regression of randomized controlled trials. BMJ 2008; 336: 645–651. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003; 138: 98–104. [DOI] [PubMed] [Google Scholar]
- 13. Wisniacki N, Taylor W, Lye M, Wilding JP. Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. Heart 2005; 91(1): 32–37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Mason JM, Freemantle N. Coronary events with lipid‐lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 199; 281: 415–419. [PubMed] [Google Scholar]
- 15. Okura H, Asawa K, Kubo T, et al. Impact of statin therapy on systemic inflammation, left ventricular systolic and diastolic function and prognosis in low risk ischemic heart disease patients without history of congestive heart failure. Intern Med 2007; 46: 1337–1343. [DOI] [PubMed] [Google Scholar]
- 16. Almuti K, Rimawi R, Spevack D, Ostfeld RJ. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol 2006; 109: 7–15. [DOI] [PubMed] [Google Scholar]
- 17. Xu Z, Okamoto H, Akino M, Onozuka H, Matsui Y, Tsutsui H. Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II‐induced hypertensive mice. J Cardiovasc Pharmacol 2008; 51: 62–70. [DOI] [PubMed] [Google Scholar]
- 18. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129–1135. [DOI] [PubMed] [Google Scholar]